ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 3055

Evaluation of Plasma Pentraxin-3 Level in Patients with Takayasu’s Arteritis

Fatma Alibaz-Oner1,2, Kenan Aksu3, P.Sibel Yentür4, Gokhan Keser5, Guher Saruhan-Direskeneli6 and Haner Direskeneli7, 1Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, 2Department Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, 3Dept. Of Internal Medicine, Division of Rheumatology, Ege University, Dept. Of Internal Medicine, Division of Rheumatology, Ege University, Izmir, Turkey, 4Physiology, Istanbul University, Istanbul Medical Faculty, Istanbul, Turkey, 5Rheumatology, Ege University Medical Faculty, Izmir, Turkey, 6Department of Physiology, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey, 7Rheumatology, Marmara University, Faculty of Medicine, Istanbul, Turkey

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Biomarkers and takayasu arteritis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Session Title: Vasculitis Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Assessment of disease activity is one of the major difficulties in patients with TAK during follow-up. To date, no biomarker is universally accepted to be a surrogate for active disease in TAK. In this study, we aimed to investigate  plasma Pentraxin-3(PTX-3) level and its correlation with clinical activity in patients with TAK.

Methods: The study included 94 patients (age: 43.3±13.6 years, F/M: 80/14) with TAK and 40 age and sex matched control subjects (age: 41.5±9.3 years, F/M: 28/12). All patients fulfilled the criteria of American College of Rheumatology (ACR). TAK patients were evaluated by physician’s global assessment (PGA; active/inactive) and Kerr’ criteria(if available). Recently, a new composite index- ITAS2010 (Indian Takayasu Clinical Activity Score) for the clinical assessment of TAK was developed and validated. We also used ITAS2010 to assess clinical activity. Plasma samples were separated to measure PTX-3. Commercial enzyme linked immuno-sorbent assay (ELISA) kits were used for measurements of plasma PTX-3.

Results: Mean disease duration the patients was 6.8±7.2(0-42) years. Thirty-three (35.5%) patients were clinically active according to PGA. While, Kerr’s activity assessment was available in 79 patients, ITAS2010 was available in 88 patients. Twenty-five(31.6%) patients were active according to the Kerr’s, 28(31.8%) patients were active according the ITAS2010. Plasma Ptx3 level was significantly higher in TAK compared to healthy controls(3,5±2,5 nanogram(ng)/ml vs. 2,5±1,6 ng/ml, p=0.029). PTX-3 level was found similar between active and inactive patients according to all assessment tools( PGA, Kerr’ and ITAS2010)(Table 1). PTX-3 level significantly correlated with  only serum CRP level. PTX-3 level was also similar between taking corticosteroid treatment and not taking.

Conclusion: Although plasma PTX-3 levels were higher in patients with TAK compared to healthy controls, we observed no association with disease activity. PTX-3 level was  similar between active and inactive patients according to all activity assessment tools such as PGA, Kerr’ and ITAS2010. Our results that PTX-3 level  has limited role as a biomarker for active disease in TAK.

Table 1: Plasma pentraxin-3 levels according to different activity assessment tools.

 

Plasma pentraxin-3 level (ng/ml)

P value

PGA

Active

3.2±2.4

 

0.442

Inactive

3.6±2.4

Activity

by Kerr et al

Active

3.7±2.2

 

0.981

Inactive

3.6±2.5

ITAS2010

Active

3.9±2.5

 

0.214

Inactive

3.3±2.3

ITAS-A

Active

4.2±2.6

 

0.147

Inactive

3.3±2.3

PGA:Physician’s global assessment, ITAS: Indian Takayasu Clinical Activity Score


Disclosure: F. Alibaz-Oner, None; K. Aksu, None; P. S. Yentür, None; G. Keser, None; G. Saruhan-Direskeneli, None; H. Direskeneli, None.

To cite this abstract in AMA style:

Alibaz-Oner F, Aksu K, Yentür PS, Keser G, Saruhan-Direskeneli G, Direskeneli H. Evaluation of Plasma Pentraxin-3 Level in Patients with Takayasu’s Arteritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/evaluation-of-plasma-pentraxin-3-level-in-patients-with-takayasus-arteritis/. Accessed March 21, 2023.
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-plasma-pentraxin-3-level-in-patients-with-takayasus-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences